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Protection against insulitis and diabetes by active vitamin D, 1,25-dihydroxyvitamin D3
(1,25(OH)2D3), in nonobese diabetic mice has until now mainly been attributed to its immuno-
modulatory effects, but also protective effects of this hormone on inflammation-induced -cell
death have been reported. The aim of this studywas to clarify themolecularmechanisms bywhich
1,25(OH)2D3 contributes to -cell protection against cytokine-induced -cell dysfunction and
death. Human andmouse islets were exposed to IL-1 and interferon- in the presence or absence
of 1,25(OH)2D3. Effects on insulin secretionand-cell survivalwereanalyzedbyglucose-stimulated
insulin release and electron microscopy or Hoechst/propidium iodide staining, respectively. Gene
expression profiles were assessed by Affymetrix microarrays. Nuclear factor-B activity was tested,
whereas effects on secreted chemokines/cytokineswere confirmedbyELISAandmigration studies.
Cytokine exposure caused a significant increase in -cell apoptosis, which was almost completely
prevented by 1,25(OH)2D3. In addition, 1,25(OH)2D3 restored insulin secretion from cytokine-ex-
posed islets. Microarray analysis of murine islets revealed that the expression of approximately
4000geneswasaffectedbycytokinesafter6and24hours (n4;1.3-fold;P .02), ofwhichnearly
250 genes were modified by 1,25(OH)2D3. These genes belong to functional groups involved in
immune response, chemotaxis, cell death, andpancreatic-cell function/phenotype. In conclusion,
these findings demonstrate a direct protective effect of 1,25(OH)2D3 against inflammation-in-
duced -cell dysfunction and death in human and murine islets, with, in particular, alterations in
chemokine production by the islets. These effects may contribute to the beneficial effects of
1,25(OH)2D3 against the induction of autoimmune diabetes. (Endocrinology 155: 736–747, 2014)
Type 1 diabetes (T1D) is an autoimmune disease char-acterized by immune cell infiltration into the islets of
Langerhans and a progressive destruction of the insulin-
secreting -cells. This autoimmune attack is mediated by
the release of proinflammatory cytokines, such as IL-1,
interferon- (IFN-), and TNF-, along with the produc-
tionofother cytotoxic factors, suchas reactiveoxygenand
nitrogen species, and direct cell killing involving Fas re-
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ceptor/Fas ligand and perforin/granzyme (1, 2). Previous
in vitro studies have demonstrated that exposure of hu-
man, mouse, and rat islets, as well as clonal -cell lines, to
a combination of cytokines triggers functional impair-
ment and cell death (3). Cytokine exposure induces -cell
apoptosis by activation of signaling pathways, mainly
controlled by the transcription factors nuclear factor B
(NF-B) and signal transducer and activator of transcrip-
tion-1 (STAT-1). This, in turn, leads to nitric oxide pro-
duction, endoplasmic reticulum stress, and increased
chemokine production resulting in increased local inflam-
mation and progressive -cell death (1).
Aside from its long-known role in calcium/phosphate
homeostasis andbonehealth, theactive formofvitaminD,
1,25-dihydroxyvitamin D3 (1,25(OH)2D3), has been
identified as a modulator of the immune system playing a
significant role in thedefenseagainst autoimmunediseases
including T1D (4, 5). In support of this, vitamin D defi-
ciencyhas been linked to an increased incidence ofT1D (6,
7), whereas supplementation with vitamin D prevents or
delays the onset of T1D (unpublished personal commu-
nication with T. Takiishi). The ubiquitous expression of
the receptor for vitamin D (VDR) includes -cells (8), and
some evidence exists that 1,25(OH)2D3 exerts direct pro-
tective effects on the -cell (9). Whether or not
1,25(OH)2D3 is capable of ameliorating in vitro cytokine-
impaired insulin release and protection against cytokine-
induced cell death remains controversial (10–14). At-
tempts have alreadybeenmade to identify themechanisms
responsible for a potential protection of islet function and
survival by 1,25(OH)2D3 (9). There are no studies, how-
ever, aiming at clarifying the global mechanisms behind
these beneficial effects in pancreatic -cells.
We have addressed this question by investigating the
protective effects of 1,25(OH)2D3 on -cell function and
survival in human and mouse islets. For further in-depth
analysis of the pathways involved, we performed Af-
fymetrix microarray and immunoprecipitation assay
(IPA) analysis to identify global gene expression changes
induced by 1,25(OH)2D3 in mouse pancreatic islets ex-
posed to IL-1 and IFN-. We investigated in detail the
genes and gene networks affected by the proinflammatory
cytokines and identified restorative effects of
1,25(OH)2D3 on different functional groups such as
chemokines, NF-B-related genes, metabolic genes, and
-cell transcription factors. These alterations in gene ex-
pression profile correlate with the observed protective ef-
fects on -cell function and survival, showing that
1,25(OH)2D3 has important direct protective effects on
-cells in an inflammatory setting. These findings, to-
gether with the well-known effects of 1,25(OH)2D3 as an
immunomodulatory agent, provide a rationale for the use
of 1,25(OH)2D3 or analogs in the prevention or treatment
of T1D.
Materials and Methods
The methods for chemotaxis experiments and NF-B ac-
tivity assay are provided as Supplemental Data published on
The Endocrine Society’s Journals Online web site at
http://endo.endojournals.org.
Preparation and culture of human islets
Human islets were prepared by enzymatic digestion and den-
sity gradient purification (15, 16) from pancreata of 6 multior-
gan donors (age 65  21 years; body mass index, 26.3  5.4
kg/m2) and cultured in M199 medium containing 5.5 mM glu-
cose, supplemented with 10% (vol/vol) serum and 100 U/mL
penicillin, 100 g/mL streptomycin, 50 g/mL gentamicin, and
750 ng/mL amphotericin B (Sigma-Aldrich) (15, 16). The islets
were incubated for 24 hours either with or without 108M
1,25(OH)2D3 (Sigma-Aldrich) and subsequently cultured for 48
hours with 50 U/mL IL-1 and 1000 U/mL IFN- (Roche Di-
agnostics S.p.A.) with or without 108M 1,25(OH)2D3.
Isolation and culture of mouse pancreatic islets
Isletswere isolated from2- to 3-week-oldmaleC57BL/6mice
(Harlan) as previously described (17) and exposed for 6 and 24
hours to 4 different conditions: 1) vehicle (0.000625% ethanol);
2) 1,25(OH)2D3 (10
8 M); 3) IL-1 (50 U/mL), IFN- (100
U/mL) and vehicle; and 4) 1,25(OH)2D3, IL-1 and IFN-. Hu-
man IL-1was a gift fromDr. C.W. Reinolds, National Cancer
Institute, National Institutes of Health, Bethesda, MD. Murine
IFN- and 1,25(OH)2D3were obtained fromPeprotech and Sig-
ma-Aldrich, respectively. All animal experimentswere approved
by the Ethics Commision of the KU Leuven.
Human islet cell death and ultrastructure analysis
Assessment of human islet cell death and ultrastructure anal-
ysis were performed by electronmicroscopy studies as described
previously (18, 19). Briefly, cells were considered dead on the
basis of any of the following criteria: Loss of plasma membrane
integrity, fragmentation into discrete bodies, and engulfment of
cell corpse or its fragments by an adjacent cell. The presence of
marked chromatin condensation and/or blebs was considered as
an indication of apoptosis. For morphometric studies, 25 mi-
crographs, obtained at10 000, were analyzed by overlay with
a graticule (11 11 cm) composed of 169 points. For the study
of insulin granules, volumedensity (VD), expressed asmilliliters/
100 mL tissue (ml%), was calculated according to the formula:
VD Pi/Pt, where Pi is the number of points within the subcel-
lular component, and Pt is the total number of points.
Determination of murine islet cell death and rat
INS-1E cells
Murine islets were exposed to cytokines for 6 and 24 hours in
the presence or absence of 1,25(OH)2D3 as described earlier
(Isolation and culture ofmouse pancreatic islets). INS-1E cells (a
kind gift from Professor C. Wollheim, Centre Medical Univer-
sitaire, Geneva, Switzerland), were exposed to cytokines for 24
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hours (10 U IL-1 100 U IFN-), in the presence or absence of
1,25(OH)2D3 (10
8M) either coincubated or preincubated for
24 hours. Following 20 minutes of incubation with 50 g/mL
Hoechst 33342 and 5 g/mL propidium iodide (Life Technolo-
gies) at 37°C, the percentage of apoptosis in each islet was esti-
mated or 500 INS-1E cells were counted on an inverted fluores-
cence microscope by two observers, one of them being unaware
of sample identity.
Glucose-stimulated insulin secretion from human
islets
For insulin secretion studies of human islets, which were per-
formed as previously detailed (18, 19), islets were first kept at
37°C for 45 minutes in Krebs-Ringer bicarbonate, 0.5% (vol/
vol) albumin, pH 7.4, containing 3.3 mM glucose (wash-out
phase). Next, the medium was replaced with Krebs-Ringer bi-
carbonate containing 3.3 mM glucose to assess basal secretion
for 45 minutes followed by a further 45-minute incubation with
16.7 mM glucose to assess insulin response to acute challenge.
Insulin was quantified using an immunoradiometric assay
(Pantec Forniture Biomediche).
Glucose-stimulated insulin secretion from murine
islets
After 24 hours of culture in medium supplemented with cy-
tokines in the presence or absence of 1,25(OH)2D3, 15–20 islets
were washed 3 times in glucose-free HEPES-Krebs buffer and
incubated at 37°C and 5%CO2 for 30minutes, after which part
of the supernatant was stored at20°C for further analysis, and
islets were incubated for another 2 hours inHEPES-Krebs buffer
containing 3 or 30 mM glucose at 37°C and 5% CO2. Super-
natants were stored at20°C. The islets were washed 3 times in
ice-cold PBS and placed in a 1:2 mix of ice-cold PBS and extrac-
tion buffer (182 mM H3PO4, 83% EtOH) overnight at 4°C.
Then, the islets were sonicated and centrifuged at 3500 rpm for
10 minutes, and supernatants were stored at 20°C. Insulin
concentrations were measured with a commercial insulin ELISA
kit (Mercodia) on the Victor3 1420 Multilabel Counter
(PerkinElmer). Final values of glucose-stimulated insulin secre-
tion (GSIS) were calculated as insulin released over 2 hours,
divided by the total insulin content.
Chemokine and cytokine secretion
The concentrations of secreted chemokines and cytokines in
culture supernatants of murine islets were determined by either
ELISA (R&D Systems) or FlowCytomix assay (eBioscience) ac-
cording to the manufacturer’s instructions.
RNA isolation, reverse transcription, and
quantitative real-time PCR (qRT-PCR)
Total RNA from murine islets was extracted using the
RNeasy Micro Kit (Qiagen) and from human islets using the
PureLinkRNAminiKit (Life Technologies). cDNA synthesis for
mouse and human islets was done using SuperScript II Reverse
Transcriptase (Invitrogen) or the iScript cDNA Synthesis Kit
(Bio-Rad Laboratories), respectively. qRT-PCR was performed
with gene-specific forward and reverse primers using either Fast
SYBR Green Master Mix or a gene-specific TaqMan probe in
combination with TaqMan Fast Universal Master Mix (Life
Technologies). Sampleswere analyzed on the StepOnePlus Real-
Time PCRSystem (Life Technologies). RelativeRNAexpression
was obtained by means of the comparative cycle threshold (Ct)
method after normalization to the geometricalmean ofCt values
for ribosomal protein L27 (Rpl27), hypoxanthine guanine phos-
phoribosyl transferase (Hprt), and -actin.
Microarray and pathway analysis
Total RNAwas isolated as described previously (RNA iso-
lation, reverse transcription and qRT-PCR). RNAquality was
examined by the 2100 Bioanalyzer (Agilent), and samples
with an RNA integrity number above 7.5 were accepted for
microarray analysis. Amplified sense-strand DNA was gen-
erated using the Affymetrix GeneChip Whole Transcript
Sense Target Labeling Assay according to the manufacturer’s
instructions (Affymetrix). The incorporation of dUTP into the
final sense-strand DNA allowed for fragmentation and sub-
sequent biotin labeling. Labeled DNA fragments were hybrid-
ized overnight to Affymetrix GeneChip Mouse Gene 1.0 ST
Arrays. The arrays were washed and stained with streptavi-
din-phycoerythrin on an automated Affymetrix Fluidics Sta-
tion and scanned using the Affymetrix 3000 GeneScanner.
Microarray data were evaluated by manual investigation as
well as by the use of IPA software.
Statistics
The ANOVA test with Bonferroni correction or the paired
Student’s t test were applied for the in vitro experiments on
mouse and human islets. P  .05 was considered as significant.
For age and body mass index of human donors, data are pre-
sented as means  SD. For all other experiments, data are pre-
sented as means  SEM. Microarray image files were analyzed
using the Affymetrix command console software, and the robust
multichip average (RMA) algorithm was used to calculate the
signal intensities for each probe cell. Detection above back-
ground calls (absent, marginal, or present) were determined by
the XPS Bioconductor package (http://www.bioconductor.org/
packages/release/bioc/html/xps.html), and only probe sets de-
clared “present” in at least 50% of the replicates (2 of 4) in at
least 1 condition and 1 time point were considered for further
analysis.A list of differentially expressed geneswas generated for
each treatment group with the Welch’s t test using cutoff values
of P .02 and at least a 1.3 median fold change between treated
samples and respective controls. For IPA analysis (Ingenuity Sys-
tems, Inc.), statistically significant canonical pathways and cel-
lular functions were identified at P  .05 by Fisher’s exact test.
Results
Effect of 1,25(OH)2D3 on cytokine-induced islet cell
death and impaired glucose-stimulated insulin
release
We examined the effect of 1,25(OH)2D3 on the viabil-
ity of cytokine-exposed human and murine islets. As ex-
pected, electronmicroscopy revealed a significant increase
in apoptotic death after exposure of human islets to IL-1
 IFN- for 48 hours (from 1.0% to 11.0%; n 250 cells
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per condition; P .05) (Figure 1, A and B). 1,25(OH)2D3
prevented, to a large extent, this deleterious effect of cy-
tokines, with a proportion of apoptotic -cells of only
2.0% after addition of 1,25(OH)2D3 to the cytokine-
treated islet cultures (P .05). Similarly, an increased cell
death (2.8-fold)was observed inmurine islets treatedwith
IL-1  IFN- for 24 hours (19.7% with cytokine treat-
ment vs 7.0% in controls; n  10; P  .001). Again, co-
treatment of islets with 1,25(OH)2D3 partially reversed
the induction of apoptosis (to 12.6%) (P .001; n 10)
(Figure 1C). Longer exposure, ie, 48 and 72 hours, re-
vealed the same pattern of partial protection (data not
shown). Of note, treatment of rat insulin-producing
INS-1E cells for 24 hours with IL-1 IFN-, either pre-
incubated for 24 hours or coincubated with
1,25(OH)2D3, did not protect INS-1E cells against cyto-
kine-mediated cell death (data not shown), confirming
previously published findings in INS-1E cells and purified
rat -cells (10).
Next, we investigated the effect of cytokine exposure
on GSIS and the potentially protective effect of
1,25(OH)2D3 thereon. Basal insulin release in human is-
lets (at 3.3mMglucose)was 59.5U/mL and increased to
140 U/mL (P  .05; n  6) at 16.7 mM glucose, corre-
sponding to a stimulation index of 2.4. GSIS (expressed as
stimulation index) decreased significantly upon cytokine
exposure (72% of control islets; P  .05; n  6), and
returned to similar levels to that of control islets in the
presence of 1,25(OH)2D3 (99%; n 6) (Figure 2A). Vol-
ume density of insulin granules
(mL%) (Figure 2B) differed between
the experimental conditions (P .01
by ANOVA) and was 6.3 in control
-cells, 6.7 in 1,25(OH)2D3-ex-
posed cells, 3.0 with cytokines (P 
.05 vs the other groups), and 6.7 in
the presence of both 1,25(OH)2D3
and cytokines. These data were sup-
ported by similar observations in
mouse islets. Preexposure of murine
islets for 24 hours to IL-1 and
IFN- significantly decreased insulin
release during 2 hours of glucose
stimulation (30 mM) (52% of con-
trol level; P .05; n 7). This effect
was completely restoredby cocultur-
ing islets with 1,25(OH)2D3 for 24
hours prior to GSIS (P .05; n 7)
(Figure 3). 1,25(OH)2D3 alone did
not affect insulin secretion in either
murine (Figure 3) or human islets
(Figure 2A).
Gene networks regulated by IL-1 and IFN- in
murine islets of Langerhans
Exposure to IL-1 IFN- resulted in 3814 and 4439
differentially expressed genes after 6 and 24 hours, re-
spectively. Using IPA the most significant molecular and
cellular functions (Supplemental Figure 1) as well as ca-
nonical pathways (Supplemental Figure2)were identified.
Manual analysis was performed in parallel (by D.L.E.,
Supplemental Table 1). Several genes associated with
Figure 1. A and B, Prevention of apoptosis by 1,25(OH)2D3 in cytokine-exposed human islets, as
determined by electron microscopy. A, Representative images of human islets precultured for 24
hours with or without 1,25(OH)2D3 followed by 48 hours of exposure to cytokines and/or
1,25(OH)2D3. a, Control; b, 10
8 M 1,25(OH)2D3; c, 50 U/mL IL-1 and 1000 U/mL IFN-; and d,
108 M 1,25(OH)2D3, 50 U/ml IL-1 and 1000 U/mL IFN-. The black arrow in panel c indicates
an apoptotic -cell in a sample treated with cytokines; N, nucleus; IG, insulin granules; M,
mitochondria. Based on this electron microscopy the percentage of apoptotic -cells was
determined in human islets (B). Open bar, control medium; shaded bar, 108 M 1,25(OH)2D3;
solid bar, 50 U/mL IL-1 and 1000 U/mL IFN-; and hatched bar, 108 M 1,25(OH)2D3, 50 U/mL
IL-1 and 1000 U/mL IFN-. Data are presented as means  SEM (n  6 islets, $, P  .05 vs all
groups and vs cotreatment with 1,25(OH)2D3, Bonferroni corrected). C, Estimated % of
apoptotic cells in 1,25(OH)2D3- and cytokine-exposed murine islets determined by Hoechst-PI
staining. Islets were cultured for 6 and 24 hours in open bar, control medium; shaded bar, 108
M 1,25(OH)2D3; solid bar, 50 U/mL IL-1 and 100 U/mL IFN-; and hatched bar, 10
8 M
1,25(OH)2D3, 50 U/mL IL-1 and 100 U/mL IFN-. Data are presented as means  SEM (n  10
independent experiments, *, P  .001).
Figure 2. Effect of 1,25(OH)2D3 on glucose-stimulated insulin release
and volume density of insulin granules in human islets exposed to IL-
1 and IFN- Islets were precultured for 24 hours with 1,25(OH)2D3 or
control medium followed by 48 hours of exposure to cytokines in the
presence or absence of 1,25(OH)2D3. A, Stimulation index and B,
volume density of insulin granules (mL%) of human islets subjected to
the following: open bar, control medium; shaded bar, 108 M
1,25(OH)2D3; solid bar, 50 U/mL IL-1 and 1000 U/mL IFN-; and
hatched bar, 108 M 1,25(OH)2D3, 50 U/mL IL-1, and 1000 U/mL
IFN-. Data are presented as means  SEM (A: n  6 islets, *, P  .05
vs control, 1,25(OH)2D3 and 1,25(OH)2D3  cytokines (Bonferroni
corrected); B, n  250 cells studied per condition; $, P  .05 vs all
other conditions).
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NF-B and IFN- signaling were induced after 6 and 24
hours of cytokine exposure. A significant immune re-
sponse was evident by the induction of a high number of
proteasome subunits, HLA-related molecules, a clear an-
tiviral response, and an increase in the expression of a
multitude of chemokines, cytokines, and adhesion mole-
cules. IL-1 and IFN- modified the expression of genes
related to endoplasmic reticulum stress and caused an up-
regulation of apoptotic genes including several caspases,
whereas genes related to DNA damage and free radical
scavenger response were also differentially expressed. On
the other hand, there was an overall decrease in the ex-
pressionof genes involved in cell cycle aswell as glycolysis,
Krebs cycle, and lipid metabolism. A similar expression
pattern (ie, decreased expression) was detected for several
important -cell transcription factors and various hor-
mone and growth factor receptors.
Effects of 1,25(OH)2D3 on gene pathways
regulated by IL-1 and IFN- in murine islets of
Langerhans
Microarray analysis allowed for identification of genes
that were differentially expressed after exposure of islets
to 1,25(OH)2D3 in combination withIL-1 and IFN- as
compared with cytokine exposure alone. Only genes for
which the expression levels were also altered by cytokines
vs controls were considered. In total, 119 and 243 genes
were differentially expressed after 6 and 24 hours, re-
spectively, when these conditions were compared. Top
scoring molecular and cellular functions generated by
IPA (Supplemental Figure 3) included genes related to
cellular movement (ie, chemotaxis), cellular assembly
and organization, cellular function and maintenance,
and cellular development as well as cellular growth and
proliferation. Cell death, carbohydrate and lipid me-
tabolism, cell-to-cell signaling and interaction, vitamin
metabolism andmolecular transport were also affected.
Because these terms are rather general and do not take
into account the cell type in question, manual classifi-
cation was carried out in parallel (by H.W.-K.) as de-
scribed in the following sections.
Among the genes that were induced by cytokine treat-
ment, 38 and 74 genes were fully or partially normalized
after 6 and 24 hours of cotreatment with 1,25(OH)2D3,
respectively. Themain gene classeswere immune response
genes such as chemokines and cytokines as well as genes
involved in NF-B signaling. 1,25(OH)2D3 also partially
or fully reversed the cytokine-induced down-regulation of
37 and 110 genes after 6 and 24 hours of exposure, re-
spectively. This group included genes associated with me-
tabolism, transport and homeostasis of ions and other
substances, as well as transcription factors involved in
the maintenance of differentiated -cell functions. Fur-
thermore, genes involved in intracellular trafficking, ex-
ocytosis, and cytoskeletal organization were differen-
tially expressed after exposure of cytokine-treated islets
to 1,25(OH)2D3. Of note, genes involved in vitamin D
metabolism and signaling including Vdr and vitamin
D-binding protein (DBP/Gc) were clearly expressed
and the well-known 1,25(OH)2D3-target gene,
Cyp24a1, was significantly up-regulated, confirming
direct 1,25(OH)2D3 effects (Table 1 and Supplemental
Table 2).
Effect of 1,25(OH)2D3 on IL-1 and IFN--induced
expression of genes involved in NF-B signaling
and activity
Most NF-B family members and regulatory genes
were up-regulated after both 6 and 24 hours of cytokine
treatment (SupplementalTable 1).Among themost highly
induced genes were the NF-B subunit nuclear factor of
-light polypeptide gene enhancer in B-cells 2 (Nfkb2/
p52) and inhibitor of B kinase  (Ikbke/IKK), a gene
encoding an IB kinase that mediates inactivation of
NF-B inhibitors. Interestingly, a partial normalization
was observed after 24 hours of cotreatment with
1,25(OH)2D3 for p52, IKK , and the classical NF-B
inhibitors Nfkbib/IB and Nfkbie/IB (Table 1 and
Supplemental Table 2). In line with these findings, whole-
cell extracts isolated from islets after 30 minutes of cyto-
kine exposure showed an increase in p52-specific binding
Figure 3. Effect of 1,25(OH)2D3 on glucose-stimulated insulin
secretion (GSIS) (% of content) by isolated cytokine-exposed mouse
islets Prior to GSIS (consisting of 2 hours of incubation at 3 and 30
mM glucose [glc]), islets were subjected to 24 hours of in vitro culture
in the following: open bar, control medium or medium containing
shaded bar, 108 M 1,25(OH)2D3; solid bar, 50 U/mL IL-1 and 100
U/mL IFN-; or hatched bar, 108 M 1,25(OH)2D3, 50 U/mL IL-1 and
100 U/mL IFN-. Data are presented as means  SEM (n7
independent experiments; #, P  .01; $, P  .05).
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to oligos containing a NF-B consensus binding site (1.64
fold; P  .015). This binding activity was detected by an
antibody specific for active p52. Pretreatment (24 hours)
with 1,25(OH)2D3 reduced the p52-specific DNA-bind-
ing activity by 47% (1.26 fold; P  .05) (Figure 4).
Effect of 1,25(OH)2D3 on IL-1 and IFN--induced
expression of immune response genes and
chemotaxis
Genes related to chemotaxis and cytokine signaling
constituted the major cytokine-induced group partially
Table 1. Selected genes differentially regulated by treatment with 108 M 1,25(OH)2D3, cytokines (50 U/mL IL-1
and 100 U/mL IFN-), or the combination in murine pancreatic islets. Data are expressed as fold change vs respective
control (n  4 independent experiments)
6 hour (fold change) 24 hour (fold change)
Cyt vs
Con
1.25Cyt
vs Cyt
1.25 vs
Con
Cyt vs
Con
1.25Cyt
vs Cyt
1.25 vs
Con
Symbol Gene name/functional group
Vitamin D metabolism and signaling
Cyp24a1 Cytochrome P450, family 24,
subfamily a, polypeptide 1
2.74a 56.2a 98.19a 1.05 119.02a 88.95a
Vdr Vitamin D receptor 1.56b 1.06 1.19 2.25b 1.01 1.08
Gc/DBP Group-specific component/ vitamin
D-binding protein
1.13 1.02 1.09 1.27 1.2 1.24
NF-B signaling
Ikbke (IKK) Inhibitor of B kinase  9.22a 1.1 1.13 2.99a 1.31b 1.05
Nfkb2 (p52) Nuclear factor of  light polypeptide
gene enhancer in B-cells 2, p49/p100
10.76a 1.13 1.09 3.86a 1.81a 1.07
Nfkbib (IB) Nuclear factor of  light polypeptide
gene enhancer in B-cells inhibitor, 
2.7a 1.07 1.06 1.95a 1.26b 1
Nfkbie (IB) Nuclear factor of  light polypeptide
gene enhancer in B-cells inhibitor, 
3.26a 1.39a 1.08 1.49d 1.56b 1.08
Chemokines and cytokines
Ccl2 (MCP-1) Chemokine (C-C motif) ligand 2 70.4a 1.55b 2.13 15.19a 1.96c 1.01
Ccl5 (RANTES) Chemokine (C-C motif) ligand 5 3.99a 1.67b 1.13d 4.21a 1.6 1.04
Ccl8 (MCP-2) Chemokine (C-C motif) ligand 8 2.15a 1.44d 1.04 3a 1.66b 1.04
Cxcl1 Chemokine (C-X-C motif) ligand 1 14.57a 1.4b 1.24 4.06a 1.35b 1
Cxcl11 Chemokine (C-X-C motif) ligand 11 43.34a 1.4b 1.42 13.57a 3a 1.05
Cxcl16 Chemokine (C-X-C motif) ligand 16 6.24a 1.3b 1.03 8.57a 1.4d 1
Cxcl2 Chemokine (C-X-C motif) ligand 2 23.18a 1.9b 1.1 2.78d 1.25 1.17
Cxcl9 Chemokine (C-X-C motif) ligand 9 203.3a 1,17 2.2 191.01a 1.74d 1
Il15 IL-15 2.55a 1.42b 1.1b 1.64c 1.31d 1.01
Il18 IL-18 1.7a 1.44b 1.04 1.03 1.02 1.04
Il6 IL-6 26.26a 1.49d 1.16 14.77a 1.56 1.02
Transcription factors
Dll1 	-like 1 (Drosophila) 3.99a 1.39c 1.04 1.98b 1.36d 1.14d
Hes1 Hairy and enhancer of split 1
(Drosophila)
1.39b 1.12 1.19d 1.6c 1.41c 1.01
Id2 Inhibitor of DNA binding 2 2.11a 1.34b 1.26b 2.01b 1.22 1.17
Isl1 ISL1 transcription factor,
LIM/homeodomain
1.53a 1.04 1.06 3.63a 1.3d 1.03
Myc Myelocytomatosis oncogene 1.54b 1.31b 1.33d 4.74b 1.04 1
Neurod1 Neurogenic differentiation 1 1.12 1.22b 1.04 2.15b 1.43b 1.09b
Pax6 Paired box gene 6 1.35a 1.06 1.1 2.4a 1.3b 1.02
Glucose metabolism
Gck Glucokinase 1.05 1.23c 1.04 1.46b 1.32b 1.07
Idh1 Isocitrate dehydrogenase1
(NADP), soluble
1.49a 1.37a 1.26d 2.42a 1.78b 1.05
Ldha Lactate dehydrogenase A 1.11 1.01 1.06 1.94c 1.41c 1.09
Nubpl Nucleotide binding protein-like 1.08 1.15 1.15b 1.32c 1.43c 1.02
Pdha1 Pyruvate dehydrogenase E1  1 1.92b 1.3b 1.02 3.46a 1.83a 1.25b
Others
Nos2 (iNOS) Nitric oxide synthase 2, inducible 148.83a 1.27b 1.76 40.93a 1.26 1.17
This list is a short version of Supplemental Table 2 including genes of particular interest for -cells in the setting of T1D. Con, Control; 1,25,
1,25(OH)2D3; Cyt, IL-1 and IFN-.
a, P  .001; b, P  .01; c, P  .02; d, P  .05 by Welch’s t test.
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reversed by cotreatment with 1,25(OH)2D3 (Table 1 and
Supplemental Table 2). The affected genes included in-
flammatory chemokines known to attract monocytes,
neutrophils, or activated T cells and natural killer cells
(20), ie, chemokine C-Cmotif ligand 2 (CCL2/MCP-1), 5
(CCL5/RANTES), and 8 (CCL8/MCP-2), chemokine C-
X-C motif ligand 1 (CXCL1/KC), 2 (CXCL2/MIP-2), 9
(CXCL9), 11 (CXCL11/I-TAC/IP9), and 16 (CXCL16),
as well as the proinflammatory cytokines IL-6, IL-15, and
IL-18. For several of these chemokines and cytokines this
regulatory pattern was confirmed by qRT-PCR (Figure
5A) and paralleled by an altered protein secretion (Figure
5B). In general, the effects of 1,25(OH)2D3 on the expres-
sion of these genes were more marked after 6 hours, sug-
gesting an early and specific action. Interestingly, most of
the alterations in chemokine mRNA expression, by IL-1
and IFN, as well as the inhibitory effect of 1,25(OH)2D3
thereon, could be confirmed in human islets, measured
after 24 hours of treatment. Indeed, similar trends were
observed at the RNA level for the chemokines CXCL9,
CXCL10, and CXCL11 as well as for the cytokines IL-6
and IL-15 (Supplemental Figure 4).
We further investigated whether exposure of islets to
1,25(OH)2D3 could inhibit the migration of elicited
monocytes toward cytokine-conditioned islet supernatant
(n  7; Figure 6). Following 3 days of exposure to cyto-
kines, the migration of monocytes increased significantly
(1.55-fold compared with control; P .02), whereas this
migration was significantly lower for cotreatment with
1,25(OH)2D3, as comparedwith cytokine exposure alone
(1.28-fold; P  .01).
Effect of 1,25(OH)2D3 on cytokine-impaired
expression of genes involved in maintenance of a
differentiated -cell function
Generally, the genes involved in development, differ-
entiation, and function of -cells displayed an early (6
hours) and sustained (24 hours) decrease following cyto-
kine treatment (Supplemental Table 1). The transcription
factors, paired box gene 6 (Pax6), neurogenic differenti-
ation 1 (NeuroD1), and the LIMhomeodomain transcrip-
tion factor Isl1, all displayed reduced expression levels
upon cytokine treatment. These effects were partially re-
versed by 1,25(OH)2D3 after 24 hours. The effect onPax6
and Isl1 was confirmed by qRT-PCR (Figure 7). More-
over, we detected an induction of the notch ligand 	-like
1 (Dll1) as well as the downstream target gene, hairy and
enhancer of split 1 (Hes1), by IL-1 and IFN-. However,
this was partially prevented upon cotreatment with
1,25(OH)2D3. These effects of cytokines and cotreatment
with 1,25(OH)2D3 were observed at both time points for
Dll1 but at 24 hours only for Hes1. Myelocytomatosis
oncogene (Myc) and the target gene inhibitor of DNA
binding 2 (Id2) displayed increased expression levels fol-
lowing exposure to cytokines at 6 and 24 hours, whereas
1,25(OH)2D3 decreased the effect of the cytokines at 6
hours only for both targets, suggesting that the beneficial
effects of 1,25(OH)2D3 may be transitory in this context.
The effect onMyc expressionwas confirmed by qRT-PCR
(Figure 7).
Glucokinase (Gck), as well as Pdha1, encoding a com-
ponent of the pyruvate dehydrogenase complex, were
both down-regulated following 24 hours of cytokine
treatment, but expression levels were fully and partially
restored, after cotreatment with 1,25(OH)2D3, respec-
tively, a finding confirmed by qRT-PCR for Gck (Figure
7). A similar effect was observed for isocitrate dehydro-
genase 1 (Idh1), an enzyme catalyzing a pyruvate-cycling
pathway, as well as nucleotide binding protein-like
(Nubpl), which is required for assembly of the mitochon-
drial membrane respiratory chain reduced nicotinamide
adenine dinucleotide dehydrogenase (Complex I). The op-
posite pattern was detected for lactate dehydrogenase
(Ldha).
Discussion
In this study we investigated the protective actions of
1,25(OH)2D3 on islets of Langerhans in an inflammatory
setting, relevant for T1D, and the molecular pathways
Figure 4. Effect of 1,25(OH)2D3 on NF-B2/p52 binding activity of
cytokine-exposed murine islets Binding activity (OD450) was measured
per mg whole-cell extract obtained from islets precultured for 24 hours
in the presence or absence of 108 M 1,25(OH)2D3 followed by 30
minutes of culture with or without 50 U/mL IL-1 and 100 U/mL IFN-.
Open bar, control; shaded bar, 108 M 1,25(OH)2D3; solid bar, 50 U/
mL IL-1 and 100 U/mL IFN-; and hatched bar, 108 M 1,25(OH)2D3,
50 U/mL IL-1, and 100 U/mL IFN-. Data are presented as means 
SEM (n  4 independent experiments, $, P  .05).
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involved. Our data show that 1,25(OH)2D3 protects both
human andmouse islets against IL-1 and IFN--induced
apoptosis. This confirms previous reports by Riachy et al
(12, 13), showing protection of human islets and the rat
insulinoma RINm5F cell line against cytokine-mediated
apoptosis by 1,25(OH)2D3, but contrasts with our own
observations where we did not find protection against ap-
optosis induced by cytokines in fluorescence-activated cell
sorting-purified rat -cells and INS-1E cells by in vitro
exposure to 1,25(OH)2D3, nor in islets derived from in
vivo 1,25(OH)2D3-treated NOD.SCID (nonobese dia-
betic severe combined immune deficiency) mice (10).
These differences may be explained by differences in spe-
cies (mouse and human vs rat) and by differences in ex-
perimental conditions (eg, in vitro vs in vivo exposure to
1,25(OH)2D3), but not by differences due to pre- vs co-
exposure to 1,25(OH)2D3 (when testing pre- or coexpo-
sure, the differences between human/mouse on one side vs
rat on the other remained) or to different concentrations
of cytokines (in this study as well as in the previous one
from our group, the cytokine mixture was optimized for
mouse-, human-, or rat-derived cells). Of particular inter-
est, we show that 1,25(OH)2D3 not only restores -cell
apoptosis, but also -cell function in an inflammatory set-
ting, both inmurine and human islets. These observations
in human tissue are of particular relevance for the human
disease.
To understand the mechanisms involved in these ben-
eficial effects of 1,25(OH)2D3, we performed microarray
analysis on murine islets exposed to cytokines in the pres-
Figure 5. Effect of 1,25(OH)2D3 on mRNA and protein expression of chemokines and cytokines in IL-1- and IFN--treated murine islets. Islets
were cultured for 6 and 24 hours with the following: open bar, control medium; shaded bar, 108 M 1,25(OH)2D3; solid bar, 50 U/mL IL-1 and
100 U/mL IFN-; and hatched bar, 108 M 1,25(OH)2D3, 50 U/mL IL-1, and 100 U/mL IFN-. A, mRNA expression determined by qRT-PCR and B,
protein secretion assessed by ELISA. Data are presented as means  SEM (n4–7 independent experiments; *, P  .001; **, P  .002; #, P  .01;
##, P  0.02; $, P  0.05).
Figure 6. Effect of 1,25(OH)2D3 on chemotactic migration of
peritoneal macrophages toward islet medium Islets were exposed in
vitro for 72 hours to the following: open bar, control medium; shaded
bar, 108 M 1,25(OH)2D3; solid bar, 50 U/mL IL-1 and 100 U/mL IFN-
; and hatched bar, 108 M 1,25(OH)2D3, 50 U/mL IL-1, and 100 U/
mL IFN-. Data are presented as means  SEM (n  7 independent
experiments; #, P  .01; ##, P  .02).
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ence or absence of 1,25(OH)2D3. We confirm the dra-
matic alterations taking place in-cells exposed to inflam-
matory cytokines that ultimately result in -cell
dysfunction and death, and the data are fully in line with
previous reports studying rat or human islets or rodent-
derived -cell lines (21–23). Integrated signaling cascades
are affected by the inflammatory cytokines, someofwhich
may launch pathways that are crucial in the dialogue be-
tween the -cell and the immune system (3). Importantly,
this analysis indicated that nearly 4000 genes are affected
by cytokines after 6 and 24 hours of exposure.
1,25(OH)2D3 counteracted the effects of cytokines on
nearly 250 genes. These modified genes belong to func-
tional groups involved in immune response, chemotaxis,
cell death, and pancreatic -cell function/phenotype, pro-
viding a mechanistic explanation for the beneficial effects
of the hormone in the context of cytokine-induced -cell
dysfunction and death.
NF-B has been described as a “master switch” for the
gene networks regulating cytokine-induced -cell dys-
function and death and is believed to be proapoptotic in
rodent -cells in vitro (24, 25) and in vivo (26). It is still
controversialwhether this is also the case inhuman-cells,
with some studies showing thatNF-Bmodulates keypro-
apoptotic pathways (27, 28), whereas others suggest a less
relevant role for this transcription factor (29). The ability
of 1,25(OH)2D3 to decrease several NF-B signaling
members and especially the binding activity of p52 sub-
units and thus oppose the induction of NF-B-related
genes by IL-1 and IFN- suggests that 1,25(OH)2D3may
protect islets against apoptosis through effects on NF-B
signaling. Two of the affected genes, p52 and IKK, have
traditionally been considered to be part of the noncanoni-
cal NF-B pathway, which is triggered by developmental
stimuli and regulates cellular processes such as prolifera-
tion and survival (30–32). Cross talk between the canon-
ical and noncanonical pathways is believed to take place
(30). In addition, p52/ mice display an autoimmune
phenotype (33), whereas IKK has been reported to play
a critical role in the antiviral response triggered by IFN
(34). Previous reports that 1,25(OH)2D3 down-regulates
p65/RelA and p52 in human islets (13) and inhibits nu-
clear translocation of NF-B complexes in murine islets
(35) and RINm5F cells (12) support a role for NF-B
signaling in 1,25(OH)2D3-mediated protection of islets.
The reported role for the antiapoptotic A20 protein and
for Fas receptor in this protective effect of 1,25(OH)2D3
in human islets (12, 13), however, could not be con-
firmed in the present study. Again species differences,
differences in cytokine cocktail, or differences in pre- vs
coexposure of cytokines and 1,25(OH)2D3may explain
these discrepancies.
A group ofmolecules that has been identified as central
in the dialogue between-cells and the immune systemare
chemokines, which are produced by the -cells under in-
flammatory attack (3, 36). These chemokines are the gene
class most markedly affected by 1,25(OH)2D3 in the pres-
ent study, an observation in linewith previous reports (10,
35, 37). Importantly, our data significantly increases the
number of known IL-1- and IFN--induced cytokines
and chemokines the expression of which is reversed by
1,25(OH)2D3, and we could confirm a similar regulation
in human islets. This, together with the observed coun-
teractive effect of 1,25(OH)2D3 on migration of mono-
cytes toward islet supernatant, suggest that 1,25(OH)2D3
may prevent or attenuate insulitis in T1D. In support of
this concept, in vivo studies have documented that pretreat-
ment with 1,25(OH)2D3 or an analog reduces T cell recruit-
ment to the islets of prediabetic nonobese diabetic (NOD)
mice orNOD.SCIDmice transferredwithCD4 andCD8
T cells from recently diabetic NOD mice (10, 35).
Further, and in agreement with previous observations
in cytokine-treated rat -cells (23), we observed that cy-
tokines induce a decline in the expression of genes in-
volved in glucose and lipid metabolism as well as a de-
creased expression of genes encoding various hormone
and growth factor receptors, thus contributing to -cell
dysfunction. 1,25(OH)2D3 partially restores the expres-
Figure 7. Effect of 1,25(OH)2D3 on mRNA expression of Gck, Isl1,
Pax6, and Myc in cytokine-exposed murine islets Islets were exposed
in vitro for 6 and 24 hours to the following: open bar, control medium;
shaded bar, 108 M 1,25(OH)2D3; solid bar, 50 U/mL IL-1 and 100
U/mL IFN-; and hatched bar, 108 M 1,25(OH)2D3, 50 U/mL IL-1,
and 100 U/mL IFN-. Data are presented as means  SEM (n  4–7
independent experiments; *, P  .001, **, P  .002; ##, P  .02; $,
P  .05).
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sion of key -cell transcription factors, like Pax6, Neu-
roD1 and, to a minor extent, Isl1. These genes are impor-
tant not only for development of the endocrine pancreas
and-cells but also formaintaining the functionofmature
-cells (38–42). There is evidence that -cells regenerate
during T1D (43). However, such regeneration would be
limited by the continuous autoimmune attack involving
activation of notch signaling and consequent dedifferen-
tiation of -cells. According to the present data, such ef-
fects may be partially antagonized by 1,25(OH)2D3
through a decline in the expression of the notch ligand
Dll1 and the downstream targetHes1. Similar effectswere
seen on the expression of Myc and the target gene Id2,
which encode proteins that prevent binding of transcrip-
tion factors such as NeuroD1 to target genes (44, 45).
Several genes involved in glucosemetabolism aswell as
transcription factors playing a role in maintaining a dif-
ferentiated -cell phenotype are altered by cytokines and
partially normalized by 1,25(OH)2D3. These may be re-
sponsible for the underlying mechanisms resulting in the
improved GSIS by 1,25(OH)2D3. As such, the capacity of
1,25(OH)2D3 to reverse the decline in expression levels of
Gck as well as the pyruvate dehydrogenase component
Pdha1may contribute to ameliorate islet function during
exposure toproinflammatory cytokines. This is supported
by a previous observation of impaired GSIS in islets iso-
lated from a mouse model of -cell specific PDHA1 defi-
ciency (46). In the second and more prolonged phase of
insulin release, other factors than regulation of ATP-de-
pendent potassium channels by cytosolic ATP levels have
been implicated including pyruvate cycling. IDH1 cata-
lyzes one of the pyruvate cycling pathways in which cy-
tosolic isocitrate is oxidized to-ketoglutarate, which can
then reenter the mitochondrial Krebs cycle. The observed
early normalization (6 hours) of Idh1 expression by
1,25(OH)2D3 in cytokine-exposed islets may contribute
to improve GSIS, because it has previously been demon-
strated that suppression of Idh1 expression by small in-
terfering RNA in INS-1 cells and rat islets impairs GSIS
(47). On the other hand, overexpression ofLdha, which is
usually expressed at low levels in -cells to ensure that
pyruvate is primarily channeled into aerobic mitochon-
drial metabolism (48), has been shown to cause a decline
in GSIS in mouse insulin-producing MIN6 cells (49). An
enhanced expression of Ldha is exactly what we observe
following 24 hours of exposure to IL-1 and IFN-. In-
terestingly, combined treatment with 1,25(OH)2D3 con-
fers a partial protection against this cytokine-induced
modification.
The present study is a follow-up of a previous study, in
which we described the effects of 1,25(OH)2D3 on whole
murine islets without the concurrent exposure to cyto-
kines (50).Major findingswere that 1,25(OH)2D3 altered
the expression of genes related to cell cycle and growth as
well as several ion/solute transport genes. Of particular
interest, a potential improvement of insulin secretion by
1,25(OH)2D3 was suggested by modulatory effects on
genes involved in cytoskeletal organization and intracel-
lular trafficking aswell as other genes previously linked to
insulin release. Compared with the present study, it ap-
pears that 1,25(OH)2D3-driven gene-regulatory events
observed during cytokine exposure are dependent on cy-
tokine signaling because the most important
1,25(OH)2D3-target genes during cytokine exposure dif-
fer from thosemodified by 1,25(OH)2D3 under basal con-
dition.Overall, our current and previous data suggest that
any major beneficial effects of superphysiological
1,25(OH)2D3 levels will become apparent only during
stressful conditions such as exposure to cytokines in T1D.
Early (6 hours) and late (24 hours) time points were
chosen for islet culture and subsequent gene expression
analysis in order to identify primary and secondary targets
of 1,25(OH)2D3 in the setting of cytokine exposure. Al-
though an early and sustained induction of NF-B related
geneswasobservedduring cytokine exposure,wedetected
only late counteractive effects by 1,25(OH)2D3, affecting
preferentially genes related to apoptosis. It is thus plausi-
ble that 1,25(OH)2D3 protects against apoptosis through
the late inhibition of NF-B signaling. In contrast, our
data suggest that normalizing actions of 1,25(OH)2D3 on
chemokine and cytokine expression are early and poten-
tially direct events, thus suggesting theymayoccur, at least
in part, independently of NF-B signaling. We also ob-
served an early, but minor, normalization by
1,25(OH)2D3 cotreatment of inducible NOS/Nos2 gene
expression. Based on these findings and previous obser-
vations by Riachy et al (12), this early inhibition of iNOS
expression may contribute to the observed effects of
1,25(OH)2D3 cotreatment on -cell transcription factors,
glucosemetabolic genes, and restoration of insulin release
as well as protection against apoptosis. The inhibition by
cytokines and normalization by cotreatment of genes re-
lated to glucose metabolism and to exocytosis, intracel-
lular trafficking, and cytoskeleton-related genes were
present either exclusively after 24 hours or with stronger
signals than at the 6-hour time point. Thus, these events
aremost likely secondary to the effects of other genes such
as the mentioned transcription factors.
In conclusion, we demonstrate that 1,25(OH)2D3 ex-
erts partial protection against cytokine-induced islet cell
death and completely restores insulin release in both hu-
man and murine islets following cytokine treatment.
A new theme emerging from our work is that
1,25(OH)2D3 ameliorates cytokine-impaired expression
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ofmetabolically relevant genes such as glucokinase aswell
as transcription factors involved in maintenance of a dif-
ferentiated -cell phenotype, providing an underlying ex-
planation for the observed protection by 1,25(OH)2D3
against cytokine-mediated decrease in GSIS. Moreover,
our results point to a major role of the NF-B-signaling
pathway in the protection by 1,25(OH)2D3 against cyto-
kine-mediated apoptosis. Finally, the most significant ef-
fect of 1,25(OH)2D3 was to antagonize the induction of a
high number of chemokines and proinflammatory cyto-
kines in islets exposed to IL-1 and IFN-, both in human
andmouse islets, associatedwith a decreasedmigration of
monocytes toward supernatant of cytokine-1,25(OH)2D3-
treated islets. These effects likely alter the dialogue between
the-cellunder inflammatoryattackandthe immunesystem
and may thus help to decrease islet infiltration during early
stages of diabetes development and contribute to prevent
-cell death in vivo. Although additional confirmations on
protein expression levels would increase the significance,
the present findings strengthen the basis for the use of
1,25(OH)2D3 in the prevention or treatment of T1D, not
onlyvia itsreportedtolerogenicactionsonimmunecells (51),
but also, as shown here, by directly acting on the -cells.
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